Non-Small Cell Lung Carcinoma
Medicine & Life Sciences
100%
Lung Neoplasms
Medicine & Life Sciences
63%
ErbB Receptors
Medicine & Life Sciences
43%
Gefitinib
Medicine & Life Sciences
38%
Small Cell Lung Carcinoma
Medicine & Life Sciences
37%
Cisplatin
Medicine & Life Sciences
36%
Drug Therapy
Medicine & Life Sciences
27%
Mutation
Medicine & Life Sciences
24%
Ninomiya, T. ,
Ishikawa, N. ,
Kozuki, T. ,
Kuyama, S. ,
Inoue, K. ,
Yokoyama, T. ,
Kanaji, N. ,
Yasugi, M. ,
Shibayama, T. ,
Aoe, K. ,
Ochi, N. ,
Fujitaka, K. ,
Kodani, M. ,
Ueda, Y. ,
Watanabe, K. ,
Bessho, A. ,
Sugimoto, K. ,
Oze, I. ,
Hotta, K. &
Kiura, K. ,
10月 2023 ,
In: Lung Cancer. 184 , 107349.
研究成果 › 査読
Afatinib
100%
Bevacizumab
73%
ErbB Receptors
62%
Progression-Free Survival
59%
Non-Small Cell Lung Carcinoma
58%
Tominaga, Y. ,
Fujii, M. ,
Sadahira, T. ,
Katayama, S. ,
Iwata, T. ,
Nishimura, S. ,
Bekku, K. ,
Edamura, K. ,
Kobayashi, T. ,
Kobayashi, Y. ,
Kiura, K. ,
Maeda, Y. ,
Wada, K. &
Araki, M. ,
2月 2023 ,
In: Molecular and Clinical Oncology. 18 ,
2 , 7.
研究成果 › 査読
Bacillus
100%
Urinary Bladder Neoplasms
96%
Tuberculosis
83%
Urinary Bladder
80%
Pathologic Constriction
80%
Takata, J. ,
Kiura, K. ,
Nakasuka, T. ,
Hirabae, A. &
Arimoto-Kobayashi, S. ,
12月 2023 ,
In: Genes and Environment. 45 ,
1 , 19.
研究成果 › 査読
4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone
100%
DNA
52%
mutagenicity
52%
Carcinogenesis
49%
repair
41%
Sato, K. ,
Takigawa, N. ,
Kubo, T. ,
Katayama, H. ,
Kishino, D. ,
Okada, T. ,
Hisamoto, A. ,
Mimoto, J. ,
Ochi, N. ,
Yoshino, T. ,
Ueoka, H. ,
Tanimoto, M. ,
Maeda, Y. &
Kiura, K. ,
2月 1 2023 ,
In: Acta medica Okayama. 77 ,
1 ,
p. 65-70 6 p. 研究成果 › 査読
polyphenon E
100%
Cyclooxygenase 2 Inhibitor
77%
Celecoxib
74%
epigallocatechin gallate
66%
Gallate
62%
Kubo, T. ,
Ichihara, E. ,
Harada, D. ,
Inoue, K. ,
Fujiwara, K. ,
Hosokawa, S. ,
Kishino, D. ,
Kawai, H. ,
Ochi, N. ,
Oda, N. ,
Hara, N. ,
Hotta, K. ,
Tabata, M. ,
Maeda, Y. &
Kiura, K. ,
9月 2023 ,
In: Respiratory Investigation. 61 ,
5 ,
p. 643-650 8 p. 研究成果 › 査読
Non-Small Cell Lung Carcinoma
100%
Elderly
75%
Confidence Intervals
33%
pembrolizumab
19%
Safety
16%